Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transcriptional adaptor 3 (TADA3) is a conserved adaptor protein that acts as a coactivator for transcriptional activators, functioning as a critical subunit of histone acetyltransferase (HAT) complexes such as PCAF and ATAC, thereby regulating chromatin accessibility and gene expression[1][2][4][5]. TADA3 is required for efficient acetylation of histones, modulates cell cycle progression, and stabilizes the tumor suppressor p53, facilitating p53-mediated DNA damage response and apoptosis[1][3][5][6]. It directly interacts with diverse transcription factors, including p53, retinoic acid receptor alpha, and estrogen receptors, as well as other coactivators, and its loss or dysfunction has been implicated in oncogenic transformation, notably in HPV-related cancers and in the progression and aggressiveness of several carcinomas[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transcriptional adaptor 3 (TADA3).